Lv12
50 积分 2026-05-17 加入
1058b GUSELKUMAB FOR PERIANAL FISTULIZING CROHN’S DISEASE: WEEK 24 RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER FUZION STUDY
1天前
求助中
Computed Tomography Enterography Detects Intestinal Wall Changes and Effects of Treatment in Patients With Crohn's Disease
23天前
已完结
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer
1个月前
已完结
Targeting IL-23 for IBD: Rationale and Progress to Date
1个月前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
1个月前
已完结
Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study
1个月前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
1个月前
已完结
Serious infection in inflammatory bowel diseases patients treated with vedolizumab, ustekinumab, JAK inhibitors, anti-TNF or aminosalicylates
3个月前
已完结
皖公网安备34019202002308
